Selected Publications
Fischer NW*, Ma YV*, Gariépy J. (2023) [*Co-first authorship] Emerging insights into ethnic-specific TP53 germline variants. J Natl Cancer Inst. Jun 23:djad106. doi: 10.1093/jnci/djad106
Saha S*, Sparkes A*, Matus EI, Lee P, Gariépy J. (2023) [*Co-first authorship] The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity. Sci Rep. 13(1):4609
Vivian Ma YH*, Sparkes A*, Saha S, Gariépy J. (2022) [*Co-first authorship] VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils. Cell Immunol. 379:104581
Alwash M and Gariépy J (2022) Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics. ACS Pharmacol Transl Sci. 5:62-69
Ma YV*, Sparkes A*, Romão E, Saha S, Gariépy J (2021) [*Co-first authorship] Agonistic nanobodies and antibodies to human VISTA. MAbs. 13(1):2003281
Matus EI, Sparkes A, Gariépy J (2020) A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells.
JCI Insight. 5(22):e141293
Fernando A and Gariépy J (2020) Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhance their intracellular delivery and photodynamic killing of cancer cells. Sci Rep. 10:2802
Prodeus A*, Sparkes A*, Fischer N, Cydzik M, Huang E, Khatri I, Young A, Woo L, Chow CW, Gorczynski R, and Gariépy J (2018) [*Co-first authorship] A synthetic cross-species CD200R1 agonist suppresses inflammatory immune responses in vivo. Mol Ther Nucleic Acids. 12:350–358
Fischer NW, Prodeus A, and Gariépy J (2018) Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity. JCI Insight. 3(15):e121364
Fischer NW, Prodeus A, Tran J, Malkin D, Gariépy J (2018) Association between the oligomeric status of p53 and clinical outcomes in Li-Fraumeni Syndrome. J Natl Cancer Inst. 110(12):1418-1421
Abdul-Wahid A, Cydzik M, Fischer NW, Prodeus A, Shively J, Martel A, Alminawi S, Ghorab Z, Berinstein NL and Gariépy J (2018) Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. Int J Cancer. 143:1963-1977
Prodeus A, Abdul-Wahid A, Sparkes A, Fischer NW, Cydzik M, Chiang N, Alwash M, Ferzoco A, Vacaresse N, Julius M, Gorczysnki RM, Gariépy J. (2017) VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses. JCI Insight. 2(18):e94308
Fischer NW, Prodeus A, Malkin D, Gariépy J. (2016) p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. Cell Cycle. 15(23):3210-3219
Samuel N, Wilson G, Id Said B, Pan A, Deblois G, Fischer NW, Alexandrova R, Casallo G, Paton T, Lupien M, Gariepy J, Merico D, Hudson TJ, Malkin D. (2016) Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. Oncotarget. 7(31):49611-49622
Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R. (2016) Tn-MUC1 DC vaccination of Rhesus macaques and a phase I/II Trial in patients with nonmetastatic castrate-resistant prostate cancer. Cancer Immunol Res. 4(10):881-892
Abdul-Wahid A, Cydzik M, Prodeus A, Alwash M, Stanojcic M, Thompson M, Huang EH, Shively JE, Gray-Owen SD, Gariépy J. (2016) Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer. 139(4):841-853
Wu FT, Lee CR, Bogdanovic E, Prodeus A, Gariépy J, Kerbel RS. (2015) Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. EMBO Mol Med. 7(6):770-787
Cydzik M, Abdul-Wahid A, Park S, Bourdeau A, Bowden K, Prodeus A, Kollara A, Brown TJ, Ringuette MJ, Gariépy J. (2015) Slow binding kinetics of SPARC-VEGF interaction limit VEGF activation of VEGF-R2 and attenuates angiogenesis. FASEB J. 29(8):3493-3505
Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariépy J. (2015) Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids. 4:e237
Prodeus A, Cydzik M, Abdul-Wahid A, Huang EH, Khatri I, Gorczynski R, Gariépy J. (2014) Agonistic CD200R1 DNA aptamers are potent immunosuppressants that prolong allogeneic skin graft survival. Mol Ther Nucleic Acids. 3:e190
Abdul-Wahid A, Huang EH, Cydzik M, Bolewska-Pedyczak E, Gariépy J. (2014) The carcinoembryonic antigen IgV-like N domain plays a critical role in the implantation of metastatic tumor cells. Mol Oncol. 8(2):337-350
Orava EW, Abdul-Wahid A, Huang EH, Mallick AI, Gariépy J. (2013) Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen. Mol Oncol.
7(4):799-811
Orava EW, Jarvik N, Shek J, Sidhu SS, Garipéy J. (2013) A short DNA aptamer that recognizes TFN-α and blocks its activity in vitro. ACS Chem Biol. 8(1):170-178
Shi PL, Binnington B, Sakac D, Katsman Y, Ramkumar S, Gariépy J, Kim M, Branch DR, Lingwood C. (2012) Verotoxin A subunit protects lymphocytes and T cell lines against X4 HIV infection in vitro. Toxins (Basel). 4(12):1517-1534
Abdul-Wahid A, Huang EH, Lu H, Flanagan J, Mallick AI, Gariépy J. (2012) A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo. Int J Cancer. 131(12):2839-2851
McCluskey AJ, Bolewska-Pedyczak E, Jarvik N, Chen G, Sidhu SS, Gariépy J. (2012) Charged and hydrophobic surfaces on the a chain of shiga-like toxin 1 recognize the C-terminal domain of ribosomal stalk proteins. PLoS One. 7(2):e31191
Mohammed AF, Abdul-Wahid A, Huang EH, Bolweska-Pedyczak E, Cydzik M, Broad AE, Gariépy J. (2012) The Pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPP-protein cargos to the cytosol of eukaryotic cells. J Control Release. 164(1):58-64
Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. (2010) Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila Pa). 3(4):438-446
Ryan SO, Turner MS, Gariépy J, Finn OJ. (2010) Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 70(14):5788-5796
Orava EW, Cicmil N, Gariépy J. (2010) Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta. 1798(12):2190-2200
Ferreira CS, Cheung MC, Bisland S, Missailidis S, Gariépy J. (2009). Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 37(3):866-876
Last updated on April-4-2023